RT Journal Article
SR Electronic
T1 Microbiota based personalized nutrition improves hyperglycaemia and hypertension parameters and reduces inflammation: A prospective, open label, controlled, randomized, comparative, proof of concept study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.12.25.23300515
DO 10.1101/2023.12.25.23300515
A1 Kallapura, Gopalakrishna
A1 Prakash, Anthony Surya
A1 Sankaran, Kumar
A1 Manjappa, Prabhath
A1 Chaudhary, Prayagraj
A1 Ambhore, Sanjay
A1 Dhar, Debojyoti
YR 2023
UL http://medrxiv.org/content/early/2023/12/28/2023.12.25.23300515.abstract
AB Recent studies suggest that gut microbiota composition, abundance and diversity can influence many chronic diseases such as type 2 diabetes. Modulating gut microbiota through targeted nutrition can provide beneficial effects leading to the concept of personalized nutrition for health improvement. In this prospective clinical trial, we evaluated the impact of a microbiome-based targeted personalized diet on hyperglycaemic and hyperlipidaemic individuals. Specifically, BugSpeaks®- a microbiome profile test that profiles microbiota using next generation sequencing and provides personalized nutritional recommendation based on the individual microbiota profile was evaluated. The test arm [microbiome-based nutrition] showed a statistically significant decrease in HbA1c level [from 8.30 ± 1.12 to 6.67 ± 0.89, p<0.001] after 90 days. The test arm, also showed a 5% decline in the systolic pressure whereas the control arm showed a 7% increase. Incidentally, a sub-cohort of the test arm of patients with >130mm Hg systolic pressure showed a statistically significant decrease of systolic pressure by 14%. Interestingly, CRP level was also found to drop by 19.5%. Alpha diversity measures showed a significant increase in Shannon diversity measure [p<0.05], after the microbiome-based personalized dietary intervention. The intervention led to a minimum 2-fold [Log2 fold change] increase in beneficial species like Phascolarctobacterium succinatutens, Bifidobacterium angulatum, Levilactobacillus brevis, and a similar decrease in non-beneficial species like Alistipes finegoldii, Sutterella faecalis. Overall, the study indicated a net positive impact of the microbiota based personalized dietary regime on the gut microbiome and correlated clinical parameters.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2022/05/042791Funding StatementThis study was funded by Leucine Rich Bio Pvt LtdAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics committee, Charak Hospital- Reg:ECR/152/Inst/MP/2021, Bhopal, India gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes